Display options
Cite
Gale RP, Lazarus HM. Liaisons Dangereuses? new drugs, physicians and the drug industry. Bone Marrow Transplant. 2020;56(2):299-302doi: 10.1038/s41409-020-0988-0.
Gale, R. P., & Lazarus, H. M. (2021). Liaisons Dangereuses? new drugs, physicians and the drug industry. Bone marrow transplantation, 56(2), 299-302. https://doi.org/10.1038/s41409-020-0988-0
Gale, Robert Peter, and Lazarus, Hillard M. "Liaisons Dangereuses? new drugs, physicians and the drug industry." Bone marrow transplantation vol. 56,2 (2021): 299-302. doi: https://doi.org/10.1038/s41409-020-0988-0
Gale RP, Lazarus HM. Liaisons Dangereuses? new drugs, physicians and the drug industry. Bone Marrow Transplant. 2021 Feb;56(2):299-302. doi: 10.1038/s41409-020-0988-0. Epub 2020 Jul 01. PMID: 32612254; PMCID: PMC7327102.
Copy Download .nbib Format: NLM
Share it on

Bone Marrow Transplant. 2021 Feb;56(2):299-302. doi: 10.1038/s41409-020-0988-0. Epub 2020 Jul 01.

Liaisons Dangereuses? new drugs, physicians and the drug industry.

Bone marrow transplantation

Robert Peter Gale, Hillard M Lazarus

Affiliations

  1. Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK. [email protected].
  2. Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH, USA.

PMID: 32612254 PMCID: PMC7327102 DOI: 10.1038/s41409-020-0988-0

[No abstract available.]

References

  1. Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15:134. - PubMed
  2. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival. An analysis of 5 years of US Food and Drug Administration approvals. JAMA. 2015;175:1992–4. - PubMed
  3. Davis C. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530. - PubMed
  4. Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes. Ann Intern Med. 2020. https://doi.org/10.7326/M19-3286 . Online ahead of print. PMID: 32203984. - PubMed
  5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64. - PubMed
  6. Gale RP, Zhang MJ. What is the P-value anyway? Bone Marrow Transpl. 2016;51:1439–40. - PubMed
  7. Gale RP, Hochaus A, Zhang MJ. What is the (p-) value of the p-value? Leukemia. 2016;30:1965–7. - PubMed
  8. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007;4:e150. - PubMed
  9. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–75. - PubMed
  10. Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists. JAMA Intern Med. 2020. https://doi.org/10.1001/jamainternmed.2020.0090 . - PubMed

Substances

MeSH terms

Publication Types